JP2018538243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538243A5 JP2018538243A5 JP2018519460A JP2018519460A JP2018538243A5 JP 2018538243 A5 JP2018538243 A5 JP 2018538243A5 JP 2018519460 A JP2018519460 A JP 2018519460A JP 2018519460 A JP2018519460 A JP 2018519460A JP 2018538243 A5 JP2018538243 A5 JP 2018538243A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- liquid phase
- peg
- biphasic
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 230000002051 biphasic effect Effects 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 34
- 229920001223 polyethylene glycol Polymers 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims 19
- 239000007790 solid phase Substances 0.000 claims 4
- 239000012071 phase Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000012455 biphasic mixture Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021038817A JP7179112B2 (ja) | 2015-10-16 | 2021-03-11 | 安定なタンパク質組成物 |
| JP2022182235A JP7547438B2 (ja) | 2015-10-16 | 2022-11-15 | 安定なタンパク質組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242412P | 2015-10-16 | 2015-10-16 | |
| US62/242,412 | 2015-10-16 | ||
| PCT/US2016/057019 WO2017066554A1 (en) | 2015-10-16 | 2016-10-14 | Stable protein compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038817A Division JP7179112B2 (ja) | 2015-10-16 | 2021-03-11 | 安定なタンパク質組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538243A JP2018538243A (ja) | 2018-12-27 |
| JP2018538243A5 true JP2018538243A5 (enExample) | 2019-07-25 |
| JP6853245B2 JP6853245B2 (ja) | 2021-03-31 |
Family
ID=57209897
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519460A Active JP6853245B2 (ja) | 2015-10-16 | 2016-10-14 | 安定なタンパク質組成物 |
| JP2021038817A Active JP7179112B2 (ja) | 2015-10-16 | 2021-03-11 | 安定なタンパク質組成物 |
| JP2022182235A Active JP7547438B2 (ja) | 2015-10-16 | 2022-11-15 | 安定なタンパク質組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038817A Active JP7179112B2 (ja) | 2015-10-16 | 2021-03-11 | 安定なタンパク質組成物 |
| JP2022182235A Active JP7547438B2 (ja) | 2015-10-16 | 2022-11-15 | 安定なタンパク質組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180289623A1 (enExample) |
| EP (1) | EP3362041A1 (enExample) |
| JP (3) | JP6853245B2 (enExample) |
| KR (1) | KR102731879B1 (enExample) |
| CN (2) | CN113827704B (enExample) |
| AU (2) | AU2016340072B2 (enExample) |
| CA (1) | CA3001346A1 (enExample) |
| EA (1) | EA036623B1 (enExample) |
| IL (2) | IL258570B2 (enExample) |
| MX (2) | MX390837B (enExample) |
| MY (2) | MY199546A (enExample) |
| WO (1) | WO2017066554A1 (enExample) |
| ZA (1) | ZA201802460B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2909777T3 (es) | 2011-11-18 | 2022-05-10 | Regeneron Pharma | Formulación de liberación prolongada que comprende micropartículas para su uso en el humor vítreo del ojo para tratar trastornos oculares vasculares |
| IL258570B2 (en) * | 2015-10-16 | 2024-07-01 | Regeneron Pharma | Stable protein preparations |
| US12156900B2 (en) | 2017-11-17 | 2024-12-03 | Amgen Inc. | VEGFR-Fc fusion protein formulations |
| PT4364724T (pt) | 2018-05-10 | 2025-12-16 | Regeneron Pharma | Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada |
| US20220054586A1 (en) * | 2018-09-10 | 2022-02-24 | Samsung Bioepis Co., Ltd. | Liquid composition comprising protein |
| CN112294760B (zh) * | 2019-07-26 | 2025-12-12 | 宁波新致生物科技有限公司 | 一种液体制剂及其应用 |
| WO2025235973A1 (en) * | 2024-05-09 | 2025-11-13 | Deep Brain Bci Corporation | Implantable medical devices for delivering therapeutics and brain-computer interface systems |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756512B2 (ja) * | 1992-09-21 | 2006-03-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 徐放性タンパク質製剤 |
| US6004549A (en) * | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
| RU2357750C2 (ru) * | 2002-12-31 | 2009-06-10 | Элтус Фармасьютикалз Инк. | Кристаллы человеческого гормона роста и способы их получения |
| CA2530113C (en) * | 2003-06-26 | 2013-08-13 | Control Delivery Systems, Inc. | Bioerodible sustained release drug delivery systems |
| CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| CN104434770A (zh) | 2006-06-16 | 2015-03-25 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| WO2008109886A1 (en) | 2007-03-08 | 2008-09-12 | The Regents Of The University Of California | Topographically engineered structures and methods for using the same in regenerative medicine applications |
| EP3000434A1 (en) | 2007-03-16 | 2016-03-30 | The Regents Of The University Of California | Nanostructure surface coated medical implants and methods of using the same |
| SG173167A1 (en) * | 2009-01-29 | 2011-08-29 | Forsight Labs Llc | Posterior segment drug delivery |
| US8623395B2 (en) * | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| CN101559041B (zh) * | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
| US8417452B2 (en) | 2009-08-19 | 2013-04-09 | General Motors Llc | System for providing information to an operator of a vehicle |
| EP2600812B1 (en) * | 2010-08-05 | 2021-09-22 | ForSight Vision4, Inc. | Apparatus to treat an eye |
| HUE054113T2 (hu) | 2010-08-05 | 2021-08-30 | Forsight Vision4 Inc | Injekciós készülék gyógyszerbejuttatáshoz |
| WO2012142318A1 (en) | 2011-04-14 | 2012-10-18 | The Regents Of The University Of California | Multilayer thin film drug delivery device and methods of making and using the same |
| BR112014029760A2 (pt) | 2012-05-30 | 2017-06-27 | Univ California | dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos |
| US9463177B2 (en) | 2012-09-10 | 2016-10-11 | The Regents Of The University Of California | Compounds and methods for modulating vascular injury |
| EP3929218A1 (en) * | 2014-07-14 | 2021-12-29 | Amgen, Inc | Crystalline antibody formulations |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| IL258570B2 (en) | 2015-10-16 | 2024-07-01 | Regeneron Pharma | Stable protein preparations |
-
2016
- 2016-10-14 IL IL258570A patent/IL258570B2/en unknown
- 2016-10-14 CN CN202111110779.9A patent/CN113827704B/zh active Active
- 2016-10-14 AU AU2016340072A patent/AU2016340072B2/en active Active
- 2016-10-14 EP EP16788338.8A patent/EP3362041A1/en active Pending
- 2016-10-14 KR KR1020187013253A patent/KR102731879B1/ko active Active
- 2016-10-14 EA EA201890979A patent/EA036623B1/ru unknown
- 2016-10-14 IL IL310557A patent/IL310557A/en unknown
- 2016-10-14 MX MX2018004695A patent/MX390837B/es unknown
- 2016-10-14 JP JP2018519460A patent/JP6853245B2/ja active Active
- 2016-10-14 CA CA3001346A patent/CA3001346A1/en active Pending
- 2016-10-14 MY MYPI2022002413A patent/MY199546A/en unknown
- 2016-10-14 WO PCT/US2016/057019 patent/WO2017066554A1/en not_active Ceased
- 2016-10-14 CN CN201680067420.9A patent/CN108348462B/zh active Active
- 2016-10-14 MY MYPI2018701358A patent/MY193964A/en unknown
- 2016-10-14 US US15/766,586 patent/US20180289623A1/en active Pending
-
2018
- 2018-04-13 ZA ZA2018/02460A patent/ZA201802460B/en unknown
- 2018-04-16 MX MX2022003376A patent/MX2022003376A/es unknown
-
2021
- 2021-03-11 JP JP2021038817A patent/JP7179112B2/ja active Active
-
2022
- 2022-01-25 AU AU2022200475A patent/AU2022200475B2/en active Active
- 2022-11-15 JP JP2022182235A patent/JP7547438B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538243A5 (enExample) | ||
| Vigata et al. | Hydrogels as drug delivery systems: A review of current characterization and evaluation techniques | |
| Liao et al. | Biogenic (R)‐(+)‐lipoic acid only constructed cross‐linked vesicles with synergistic anticancer potency | |
| JP7179112B2 (ja) | 安定なタンパク質組成物 | |
| JP2022166006A (ja) | 液体医薬組成物 | |
| Shin et al. | Controlled release of triprolidine using ethylene-vinyl acetate membrane and matrix systems | |
| RU2694406C2 (ru) | Способ и устройство для анализа поведения веществ in vitro в смоделированной физиологической среде | |
| Signor et al. | Spermidine improves fear memory persistence | |
| Lehmann et al. | Aquaporins: their role in cholestatic liver disease | |
| Shen et al. | Helper T cell (CD4+) targeted tacrolimus delivery mediates precise suppression of allogeneic humoral immunity | |
| Hutton et al. | Enhancing the transdermal delivery of ‘next generation’variable new antigen receptors using microarray patch technology: a proof-of-concept study | |
| Severs et al. | Intravenous solutions in the care of patients with volume depletion and electrolyte abnormalities | |
| Snorradottir et al. | Release of anti-inflammatory drugs from a silicone elastomer matrix system | |
| CN106031710A (zh) | 一种富马酸氟呐普拉赞的注射剂及其制备方法 | |
| AU2020203126B2 (en) | Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease | |
| CN103536566A (zh) | 盐酸雷莫司琼注射液及其制备方法 | |
| CN102415993A (zh) | 一种盐酸纳美芬药物组合物及其制备方法 | |
| JP2010254584A (ja) | 光安定性に優れたキノロン系抗菌薬含有液体製剤 | |
| ES2338400B1 (es) | Conjunto de moleculas antiangiogenicas y su uso. | |
| JP2006000482A (ja) | 生体適合性薬液製剤、その製造方法及びその保存方法 | |
| Rastogi et al. | Development and characterization of a scalable microperforated device capable of long-term zero order drug release | |
| CN102423311A (zh) | 一种奥扎格雷钠注射液及其制备方法 | |
| JP2020040998A5 (enExample) | ||
| Ullian et al. | Stimulation of cyclooxygenase 2 expression in rat peritoneal mesothelial cells | |
| ES2424872T3 (es) | Paracetamol para su utilización en el tratamiento del glaucoma |